Serum Proteomic Fingerprinting Discriminates Between Clinical Stages and Predicts Disease Progression in Melanoma Patients | Zendy

Shahzad I. Mian | Zendy; Selma Ugurel | Zendy; Erika Parkinson | Zendy; Iris Schlenzka | Zendy; Ian L. Dryden | Zendy; Lee Lancashire | Zendy; Graham Ball | Zendy; Colin S. Creaser | Zendy; Robert C. Rees | Zendy; Dirk Schadendorf | Zendy

Open Access

Serum Proteomic Fingerprinting Discriminates Between Clinical Stages and Predicts Disease Progression in Melanoma Patients

Author(s) -

Shahzad I. Mian,

Selma Ugurel,

Erika Parkinson,

Iris Schlenzka,

Ian L. Dryden,

Lee Lancashire,

Graham Ball,

Colin S. Creaser,

Robert C. Rees,

Dirk Schadendorf

Publication year - 2005

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2005.03.164

Subject(s) - medicine , disease , melanoma , oncology , cancer research

Currently known serum biomarkers do not predict clinical outcome in melanoma. S100-beta is widely established as a reliable prognostic indicator in patients with advanced metastatic disease but is of limited predictive value in tumor-free patients. This study was aimed to determine whether molecular profiling of the serum proteome could discriminate between early- and late-stage melanoma and predict disease progression.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research